See more : Revance Therapeutics, Inc. (RVNC) Income Statement Analysis – Financial Results
Complete financial analysis of Coherus BioSciences, Inc. (CHRS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Coherus BioSciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Sasol Limited (SSL) Income Statement Analysis – Financial Results
- LAMDA Development S.A. (LAMDA.AT) Income Statement Analysis – Financial Results
- BioLASCO Taiwan Co., Ltd. (6662.TWO) Income Statement Analysis – Financial Results
- PORTFOLIOMANAGER ØU INVEST BALANCE KL N (PMIOUIB.CO) Income Statement Analysis – Financial Results
- UnicoCell Biomed Co., Ltd. (6794.TW) Income Statement Analysis – Financial Results
Coherus BioSciences, Inc. (CHRS)
About Coherus BioSciences, Inc.
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 257.24M | 211.04M | 326.55M | 475.82M | 356.07M | 1.56M | 1.56M | 190.11M | 30.04M | 31.11M | 2.75M | 1.90M |
Cost of Revenue | 162.78M | 70.08M | 57.59M | 37.67M | 17.08M | 3.24M | 160.53M | 254.44M | 212.68M | 78.22M | 31.28M | 34.89M |
Gross Profit | 94.46M | 140.96M | 268.96M | 438.16M | 338.99M | -1.68M | -158.98M | -64.33M | -182.64M | -47.12M | -28.53M | -32.99M |
Gross Profit Ratio | 36.72% | 66.79% | 82.36% | 92.08% | 95.20% | -107.90% | -10,216.90% | -33.84% | -607.97% | -151.48% | -1,037.00% | -1,737.07% |
Research & Development | 109.44M | 199.36M | 363.11M | 142.76M | 94.19M | 110.24M | 162.39M | 254.44M | 213.06M | 78.22M | 31.28M | 34.89M |
General & Administrative | 0.00 | 187.98M | 161.01M | 135.28M | 132.54M | 94.18M | 71.30M | 51.60M | 36.05M | 17.56M | 7.47M | 5.53M |
Selling & Marketing | 0.00 | 10.50M | 8.70M | 3.80M | 4.50M | 2.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 185.62M | 198.48M | 169.71M | 139.08M | 137.04M | 94.18M | 71.30M | 51.60M | 36.05M | 17.56M | 7.47M | 5.53M |
Other Expenses | 0.00 | 3.82M | -283.00K | 554.00K | 2.61M | 4.69M | 3.40M | -3.88M | -4.84M | -18.60M | -12.35M | 7.01M |
Operating Expenses | 301.45M | 397.84M | 532.82M | 281.84M | 231.23M | 204.42M | 233.69M | 306.04M | 249.11M | 95.79M | 38.74M | 40.42M |
Cost & Expenses | 460.44M | 467.92M | 590.41M | 319.51M | 248.30M | 204.42M | 233.69M | 306.04M | 249.11M | 95.79M | 38.74M | 40.42M |
Interest Income | 0.00 | 30.57M | 21.56M | 20.57M | 16.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 40.54M | 32.47M | 22.96M | 21.17M | 17.60M | 9.68M | 9.55M | 7.98M | 33.00K | 3.90M | 5.29M | 1.51M |
Depreciation & Amortization | 3.79M | 3.70M | 5.66M | 4.97M | 3.26M | 3.24M | 3.40M | 3.00M | 1.87M | 674.00K | 404.00K | 221.00K |
EBITDA | -193.94M | -255.58M | -260.69M | 161.84M | 111.03M | -204.42M | -225.34M | -116.81M | -222.04M | -82.72M | -47.94M | -31.28M |
EBITDA Ratio | -75.39% | -119.91% | -80.89% | 32.97% | 31.00% | -12,835.80% | -14,700.13% | -63.02% | -745.33% | -267.72% | -1,742.57% | -1,647.34% |
Operating Income | -203.20M | -256.88M | -263.86M | 156.32M | 107.77M | -204.42M | -232.14M | -115.93M | -219.07M | -64.68M | -35.99M | -38.52M |
Operating Income Ratio | -78.99% | -121.72% | -80.80% | 32.85% | 30.27% | -13,137.28% | -14,918.77% | -60.98% | -729.23% | -207.94% | -1,308.36% | -2,028.33% |
Total Other Income/Expenses | -35.07M | -34.87M | -23.24M | -20.61M | -14.99M | -4.99M | -6.15M | -11.86M | -4.87M | -22.50M | -17.64M | 5.50M |
Income Before Tax | -238.27M | -291.75M | -287.10M | 135.71M | 92.78M | -209.41M | -238.29M | -127.79M | -223.94M | -87.18M | -53.64M | -33.02M |
Income Before Tax Ratio | -92.62% | -138.24% | -87.92% | 28.52% | 26.06% | -13,458.16% | -15,314.01% | -67.22% | -745.44% | -280.26% | -1,949.65% | -1,738.70% |
Income Tax Expense | -380.00K | 34.87M | 19.22M | 3.46M | 2.94M | 4.69M | 9.44M | 656.00K | -7.35M | -15.41M | -7.06M | 8.53M |
Net Income | -237.89M | -326.63M | -306.32M | 132.24M | 89.83M | -209.34M | -238.17M | -127.34M | -223.26M | -87.13M | -53.64M | -33.02M |
Net Income Ratio | -92.48% | -154.77% | -93.81% | 27.79% | 25.23% | -13,453.66% | -15,306.56% | -66.98% | -743.18% | -280.12% | -1,949.65% | -1,738.70% |
EPS | -2.53 | -4.21 | -4.06 | 1.85 | 1.29 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 | -1.83 |
EPS Diluted | -2.53 | -4.21 | -4.06 | 1.62 | 1.23 | -3.22 | -4.48 | -3.04 | -6.01 | -10.64 | -2.97 | -1.83 |
Weighted Avg Shares Out | 94.16M | 77.63M | 75.45M | 71.41M | 69.68M | 65.01M | 53.13M | 41.91M | 37.12M | 8.19M | 18.08M | 18.08M |
Weighted Avg Shares Out (Dil) | 94.16M | 77.63M | 75.45M | 83.49M | 73.19M | 65.03M | 53.13M | 41.91M | 37.12M | 8.19M | 18.08M | 18.08M |
Why Is Coherus BioSciences Stock Trading Higher On Tuesday?
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
Coherus BioSciences, Inc. (CHRS) Q3 2024 Earnings Call Transcript
Coherus BioSciences (CHRS) Reports Q3 Loss, Tops Revenue Estimates
Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024
Coherus BioSciences, Inc. (CHRS) Q2 2024 Earnings Call Transcript
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024
Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction
Source: https://incomestatements.info
Category: Stock Reports